NEJM
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
NEJM
Jul 25, 2024, 21:01 |
Blog
Caner Saygin: A testament to the fact that flow MRD is insufficient for making treatment decisions in ALL
Caner Saygin, Assistant Professor of Medicine at University of Chicago, shared a post by NEJM, on X:…
Jul 9, 2024, 10:50 |
Insight
Joseph McCollom: ACP and SIC aim to align medical care with patient goals
Joseph McCollom, Medical Oncologist at Parkview Cancer Institute, shared on X: "Vicki Jackson, American Academy of…
Jul 8, 2024, 14:55 |
Blog
Soleil Shah: Widespread acquisitions of medical practices by insurers
Soleil Shah, Resident Physician at Brigham and Women's Hospital, shared on X: "Our new paper in…
Jul 8, 2024, 06:36 |
Blog
Ariel Dora Stern: Four Decades of Orphan Drugs and Priorities for the Future
Ariel Dora Stern, Professor at Hasso Plattner Institute, shared on X: "Published today in the NEJM:…
Jul 1, 2024, 15:01 |
Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 27, 2024, 13:35 |
Insight
Myeloma Paper of the Day, June 27th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Great review of the pathogenesis,…
Jun 25, 2024, 03:26 |
Blog
Vivek Subbiah: Such a delight to have our paper published in a journal with the highest impact factor
Vivek Subbiah shared on LinkedIn: "2023 Impact factors for all journals are out!!! CA: A Cancer…
Jun 23, 2024, 14:50 |
Blog
Christopher Melani: Gratifying to see a trial that I started changing the lives of our patients with lymphoma
NCI CCR Pediatric Oncology Branch shared a post by Christopher Melani, Staff Clinician at the Lymphoid Malignancies Branch of the National…
Jun 20, 2024, 07:05 |
Blog
Thanos Dimopoulos: Honored to present as a LBA the DREAMM 8 at EHA this morning
Quoting Thanos Dimopoulos, Rector of the National and Kapodistrian University of Athens, on X: "Honored…
Jun 19, 2024, 09:11 |
Societies
Kai-Keen Shiu: Love all the data on neoadjuvant IO at ASCO24!
Kai-Keen Shiu, a Medical Oncology Consultant for the Gastrointestinal Oncology Service at University College London…
Jun 17, 2024, 16:14 |
Blog
Lorenz Mayr: The benefits of CAR-T therapy largely outweigh the potential risks of the CAR-T technology
Lorenz Mayr, CEO at Mayr BioMedTech Consulting, shared on LinkedIn: "Secondary Cancer Risk Is Low…
Jun 12, 2024, 17:27 |
Blog
Winette van der Graaf: Two papers in the New England Journal of Medicine in one week
Winette van der Graaf shared a post on their LinkedIn: ''Extremely proud and grateful for…
Jun 12, 2024, 05:36 |
Insight
Sarah Sammons: Fatty liver disease in breast cancer survivors
Sarah Sammons shared a post by NEJM on X/Twitter: "We see a decent amount of…
Jun 8, 2024, 03:28 |
Opinion
Udhayvir Grewal: NICHE2 out now in NEJM
Udhayvir Grewal, Hematology and Oncology Fellow at the University of Iowa Holden Comprehensive Cancer Center, shared…
Jun 8, 2024, 02:16 |
Blog
Toni Choueiri: NICHE-2 by Myriam Chalabi published in NEJM
Toni Choueiri shared a post on X: , "NICHE-2 published…
Jun 7, 2024, 14:59 |
Blog
Vincent Rajkumar: ASCO24 myeloma papers that I will be highlighting
Vincent Rajkumar shared a post on X: ''First of the NEJM ASCO24 myeloma papers that I…
Jun 7, 2024, 14:08 |
Blog
Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM
Mark Lewis shared on X: . "TLC: don't…
Jun 7, 2024, 10:36 |
Insight
Vincent Rajkumar: I’m updating my 2024 Review on myeloma for American Journal of Hematology
Vincent Rajkumar shared a post on X: “I’m updating my 2024 Review on myeloma for American…
Jun 7, 2024, 03:12 |
Blog
Pashtoon Kasi: Chalabi Plot now in print
Pashtoon Kasi shared a post on X: "Chalabi Plot now in print. Congratulations Myriam Chalabi/article/ With an…
Jun 5, 2024, 04:04 |
Drugs
Jon Wigginton: Very exciting phase 3 data regarding stage 3 melanoma
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “NEJM…
Jun 4, 2024, 13:13 |
Insight
Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session
Tanja Obradovic shared on LinkedIn: . "NADINA trial making history today at ASCO2024 plenary session.…
May 28, 2024, 07:48 |
Insight
Full results and Plain Language Summary for CheckMate 77T trial - NEJM
NEJM shared on X/Twitter: "In the CheckMate 77T trial, researchers assessed whether adding adjuvant nivolumab to…
May 20, 2024, 12:14 |
Blog
Pashtoon Kasi: The surgery could now be the “adjuvant” piece
Pashtoon Kasi shared on LinkedIn: "Here’s a provocative from one of my colleagues: Instead of calling…
May 18, 2024, 09:06 |
Blog
Jarushka Naidoo: Perioperative Nivolumab in Stage IIA-IIIB NSCLC
Jarushka Naidoo shared on X/Twitter: ''Ph III CM77T trial at NEJM: Perioperative Nivolumab in Stage…
May 18, 2024, 08:33 |
Blog
Rami Manochakian: Results of Checkmate 77T trial of
Rami Manochakian shared a post on X/Twitter: ''Hot Off The Press. Just published at NEJM.…
May 15, 2024, 09:38 |
Blog
Tanja Obradovic: Important PDUFA on June 12th is coming up
Tanja Obradovic shared a post on LinkedIn: "Important PDUFA on June 12th is coming up that…
May 14, 2024, 16:28 |
Blog
Christian Rolfo: Great editorial by Ticiana Batista and Suresh S. Ramalingam on 20 years of EGFR
Christian Rolfo, Associate Director Clinical Research Center of Thoracic Oncology at The Tisch Cancer Institute…
May 10, 2024, 12:42 |
Dialogues
OncoThon: Childhood Cancer with Gevorg Tamamyan, Khaled Ghanem, Jaume Mora, Leo Kager
Oncothon is a telethon spanning 24 hours, dedicated to gathering donations for childhood cancer research.…
May 2, 2024, 13:23 |
Insight
Marco Donia: Welcoming the Era of Gene Editing in Medicine
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: "Autologous…
Apr 27, 2024, 15:25 |
Insight
Gregg Margolis: A must-read by Joshua M. Sharfstein and Lawrence Gostin in NEJM on the Supreme Court's historical role in protecting the public's health
Gregg Margolis, Director of Health Policy Fellowships and Leadership Programs at the National Academy of…
Apr 25, 2024, 20:18 |
Positive
Vivek Subbiah: HUGE MILESTONE in all of medicine and a huge win for patients and families with sickle cell disease and β-Thalassemia
Quoting Vivek Subbiah's post on X/Twitter: "Hot off the press! HUGE MILESTONE in all of…
Apr 20, 2024, 06:03 |
Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Apr 15, 2024, 13:28 |
Insight
Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn: ''I am thrilled…
Apr 15, 2024, 01:09 |
Blog
Antonio Passaro: Our editorial on the groundbreaking ALINA trial
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on X/Twitter: "Just published in…
Apr 13, 2024, 13:34 |
Blog
Vivek Subbiah: An editorial describes the science behind one strategy using a CAR T cell
Vivek Subbiah shared on X/Twitter: "Most patients diagnosed with glioblastoma die within a year, so innovative…
Apr 13, 2024, 09:40 |
Drugs
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X: "Hot off…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Mar 25, 2024, 13:10 |
Insight
David Gandara: Multi-omics approach to plasma testing proves effective in colorectal cancer screening
Yuji Uehara, Medical Oncologist at National Cancer Center Hospital East, Komagome Hospital, shared a post…
Mar 19, 2024, 20:14 |
Blog
Vivek Subbiah: Nice to see CAR-T cells showing early signals of activity in Glioblastoma in a Phase 1
Vivek Subbiah shared a post on LinkedIn: "Nice to see CAR-T cells showing early signals of…
Mar 17, 2024, 15:26 |
Blog
Bryan D. Choi: NEJM published our clinical study of a novel CART Cell in patients with Glioblastoma
Bryan D. Choi, Neurosurgeon and Scientist at Massachusetts General Hospital, posted on X/Twitter: "Today, NEJM…
Mar 2, 2024, 18:48 |
Blog
Fadi Haddad: Out in NEJM rusfertide in Polycythemia vera
Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:…
Jan 20, 2024, 16:47 |
Insight
Vivek Subbiah: GPT-4 is outperforming 99.98% of simulated human readers
Vivek Subbiah shared on LinkedIn: ''The performance of the newly released AI GPT-4 in diagnosing…
Jan 11, 2024, 07:51 |
Insight
Utibe Essien: Timely new article in NEJM
Utibe R. Essien, Assistant Professor of Medicine at UCLA, shared on X: "Timely new article…
Jan 6, 2024, 12:09 |
Insight
Bishal Gyawali: Here is a list of our top 10 publications from 2023
Bishal Gyawali, Medical Oncologist and Assistant Professor at Queen’s University, shared on X: "Happy New…
Nov 4, 2023, 17:29 |
Blog
David Sebag: Delighted our letter about the PROSPECT rectal cancer trial
Quoting David Sebag-Montefiore, Director at Leeds Cancer Research Centre, on X/Twitter: “Delighted our letter about…
Oct 26, 2023, 18:17 |
Blog
Teresa Amaral: Did you know that so far the data presented at ESMO23 made it to publications in the NEJM
Teresa Amaral, recently tweeted: "Did you know that so far the data presented at ESMO23…
Oct 15, 2023, 19:08 |
Blog
Rebecca Shatsky: It’s not pink and happy, it’s not easy
Rebecca Shatsky recently shared a post by Sarah Sammons on X/Twitter, adding: "This is the…
Sep 12, 2023, 19:59 |
Insight
Bishal Gyawali: In this perspective piece out in NEJM today, we discuss finding the right balance for accelerated approval of cancer drugs in the context of the recently proposed FDA guidance.
Aug 27, 2023, 18:58 |
Insight
Vivek Subbiah: The 3rd KRAS G12C kid on the block.
According to Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute:…
Aug 27, 2023, 18:50 |
Insight
Anirban Maitra: The phase 1 data of Genentech’s KRAS G12C inhibitor Divarasib was published yesterday in NEJM.
In a Twitter post by Anirban Maitra, a Professor of Pathology and Translational Molecular Pathology,…
Aug 20, 2023, 17:45 |
Insight
Todd Scarbrough: Today I saw a lot of radonc shouting at the NEJM clouds.
Quoting Todd Scarbrough, Radiation Oncologist at Northeast Alabama Regional Medical Center on Twitter: "Today I…
Aug 18, 2023, 17:37 |
Blog
Paul Bleicher: Individuals often don't understand the downstream risk of early screening.
Paul Bleicher, Executive Partner at Ardan Equity, wrote in a recent tweet: "Individuals often don't…
Aug 12, 2023, 15:49 |
Insight
Stephen V Liu: Editorial New England Journal of Medicine from Dr. Christine Lovly, gives nice perspective on the phase III KEYNOTE 671 study in resectable non-small-cell lung cancer
All:
53
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube